SIk2 inhibitor ARN-3261 enhances sensitivity to carboplatin of both carboplatin-sensitive and resistant ovarian cancer cells in vitro, inhibits tumor xenograft growth and enhances sensitivity to both carboplatin and paclitaxel in in vivo xenograft models. Here, SIK2 is linked to ovarian cancer.